Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Sep 27, 2007
Notice of Special Meeting of Shareholders
Sep 26, 2007
Neuren launches Australian Phase 3 Trial Sites
Sep 20, 2007
Neuren completes moderate TBI safety trial
Sep 11, 2007
Change in substantial holding
Sep 07, 2007
NZ arm of Phase 3 trial commences
Aug 31, 2007
Half Yearly Report and Accounts
Aug 23, 2007
Corporate Update Presentation
Jul 31, 2007
Commitments test entity - second quarter
Jul 31, 2007
Acquisition of Motiva through Hamilton Pharmaceuticals
Jul 24, 2007
Lapse of Unquoted Options
Previous
1
2
3
4
5
6
Next